Navigation Links
Introgen Presents ADVEXIN Biomarker Data at Major Cancer Conference

LOS ANGELES--(BUSINESS WIRE)--Apr 16, 2007 - Introgen Therapeutics, Inc. (NASDAQ:INGN) reported updated ADVEXIN(R) biomarker data over the weekend in Los Angeles, California at the Annual Meeting of the American Association for Cancer Research.

Abnormality of the p53 tumor suppressor is one of the most common and fundamental molecular defects in cancer. ADVEXIN's mechanism of action is targeted to restoring p53 tumor suppressor function and the detection of abnormal p53 is a logical predictive biomarker for ADVEXIN efficacy. In a study of 28 recurrent head and neck cancer patients in Phase 2 clinical trials, abnormal p53 was shown to correlate with increased survival and tumor responses following ADVEXIN treatment.

The median survival of patients with tumors expressing the abnormal p53 biomarker was 11.6 months compared to only 3.5 months in patients whose tumors had normal p53. The association between the abnormal p53 biomarker and increased survival following ADVEXIN therapy was highly statistically significant (p=0.0007).

The abnormal p53 biomarker was also associated with a statistically significant increase in tumor responses to ADVEXIN therapy. A reduction in tumor size was observed in 40 percent of patients with the abnormal p53 biomarker compared to none (zero percent) of patients with p53 normal tumors. In addition, tumor growth control lasting for a minimum of two treatment cycles was observed in 75 percent of patients with abnormal p53 tumors compared to 27 percent of patients with a normal p53 biomarker. Both the increased reduction in tumor size and tumor growth control associated with the abnormal p53 biomarker were statistically significant (p=0.02).

Importantly, patients with abnormal p53 tumors are known to have poor responses and survival following standard treatments. These patients have the greatest need for new therapies and they achieved the most benefit from ADVEXIN t
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
2. Introgen Reports Promising Phase 1/2 Clinical Results With INGN 241 in Patients With Advanced Solid Tumors
3. Introgens Advexin Demonstrates Clinical Benefit in Inherited Cancer
4. Introgen and Clinical Collaborators to Report New Results with Advanced-Stage Cancer Therapies at Upcoming Medical Meetings
5. Preclinical Studies Identify Novel Approach for Enhancing the Anticancer Activity of Introgens INGN 241
6. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
7. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
8. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
9. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
10. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
11. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
Post Your Comments:
(Date:5/20/2013)... LONDON , BERLIN ... Arthroscopy Devices Market to ... for Minimally Invasive Procedures to Drive Future Growth" looks ... for the six arthroscopy device market segments: arthroscopes, arthroscopy ... radio frequency systems, and arthroscopy visualization systems. The report ...
(Date:5/20/2013)... , May 20, 2013  Rhythm announced today ... demonstrating a higher prevalence of gastroparesis symptoms among diabetic ... these symptoms is high among patients with both type ... significantly under-diagnosed among those with the more common type ... , MD, PhD, Associate Professor of Medicine at ...
(Date:5/20/2013)... NORTH CHICAGO, Ill. , May 20, 2013 ... today the initiation of a Phase 3 clinical ... Atrasentan) to assess the effects of the investigational ... on progression of kidney disease in patients with ... and type 2 diabetes.  SONAR is a large, ...
Breaking Medicine Technology:Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Arthroscopy Devices Market Growth 2Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Arthroscopy Devices Market Growth 3Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Arthroscopy Devices Market Growth 4Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 2Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 3Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 4AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 2AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 3AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 4AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 5AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 6
... 17, 2011 OxySure Systems, Inc., a pioneering ... powder technology, today announced that the Company has ... City of Frisco, Texas, to deliver its life-saving ... multiple Frisco municipal and community service facilities. ...
... CRANBURY, N.J., Oct. 17, 2011 Sen. ... leaders of the biopharmaceutical industry Friday unveiled the state-of-the-art ... part, by the U.S. Affordable Care Act. ... "We are committed to advancing innovative and improved biotherapeutics ...
Cached Medicine Technology:OxySure Inks 5-Year Partnership With the City of Frisco to Place OxySure/AED Packages in Its Public Venues 2OxySure Inks 5-Year Partnership With the City of Frisco to Place OxySure/AED Packages in Its Public Venues 3Senator Menendez, Lt. Governor Guadagno Unveil New Biotech Firm Oncobiologics 2Senator Menendez, Lt. Governor Guadagno Unveil New Biotech Firm Oncobiologics 3
(Date:5/20/2013)... yurbuds®, maker of the sport earphones ... the launch of its new Signature Series ITE 100 ... more signature athletes to come. Created with top players ... 100 is the perfect training partner for any athlete. ... reflective, tangle-resistant Kevlar cords, premium sound quality and a ...
(Date:5/20/2013)... Nearly 20 percent of kidneys that are recovered from ... due to factors ranging from scarring in small blood ... going too long without blood or oxygen. But, what ... "recycled" to help solve the critical shortage of donor ... and colleagues, reporting in the journal Biomaterials , ...
(Date:5/20/2013)... 2013 Dorland Health, a division ... fourth annual Case In Point Platinum Awards, recognizing ... ensuring the system is patient- and family-centric, safe ... and creative work across the healthcare system that ... transitions of care through effective care coordination across ...
(Date:5/20/2013)... Chicago (PRWEB) May 20, 2013 The ... raise $5,000 for Bright Pink®, the organization that empowers young ... by the end of 2012. Thanks to its members, ASCP ... Patterson, HT(ASCP), is involved in Relay for Life at the ... Bright Pink, he decided to donate. “I was made aware ...
(Date:5/20/2013)... (PRWEB) May 20, 2013 ... cloud and on-premise business process integration solutions, ... of its next-generation integration solution. Version ... solution that seamlessly automates business processes involving ... with meaningful business user interaction for real-time ...
Breaking Medicine News(10 mins):Health News:yurbuds Expands Best-Selling Lines with Innovative New Products 2Health News:Study suggests new source of kidneys for transplant 2Health News:Dorland Health Announces the 2013 Case In Point Platinum Awards Winners 2Health News:ASCP Members Rally Around Breast and Ovarian Cancer Awareness 2Health News:ASCP Members Rally Around Breast and Ovarian Cancer Awareness 3Health News:Adeptia Announces New Release of Enterprise Business Integration Solution 2Health News:Adeptia Announces New Release of Enterprise Business Integration Solution 3
... Southwestern Medical Center cardiologists have uncovered how a specific protein,s ... in patients with diabetes. Investigators in the mouse study also ... this protein. The new research, available online and published ... Clinical Investigation , was carried out in the laboratory of ...
... , THURSDAY, March 1 (HealthDay News) --,An estimated 4 million ... year, a new study found. A little less than 1 ... from the U.S. Forest Service used satellite imagery to analyze the ... by pavement, rooftops, grass or bare soil in 20 U.S. cities. ...
... University of North Carolina at Chapel Hill reduced damage from ... protein found in mice and humans. The study, in which ... protein focal adhesion kinase, or FAK, appeared March 1 in ... Vascular Biology . "This study shows that we can ...
... HealthDay Reporter , THURSDAY, March 1 (HealthDay News) ... their risk of developing the deadly skin cancer melanoma, a ... A called retinol could be a protective agent against melanoma; ... say. "We found a protective effect from supplemental vitamin ...
... March 1 (HealthDay News) -- White men in the United ... black men, while white women live more than five years ... when the University of California, Los Angeles-led team of researchers ... surprising discovery: In states where disparities were smallest, the differences ...
... , THURSDAY, March 1 (HealthDay News) -- Where ... have found, with city dwellers tweeting at a higher pitch ... of controlled sound recordings, researchers from the University of Copenhagen ... change the way they sing due to city buildings -- ...
Cached Medicine News:Health News:Cardiologists identify mechanism that makes heart disease worse in diabetics 2Health News:Urban Forests Disappearing: Report 2Health News:A supercharged protein reduces damage from heart attack 2Health News:Vitamin A Supplements Might Cut Melanoma Risk: Study 2Health News:Vitamin A Supplements Might Cut Melanoma Risk: Study 3Health News:Life Expectancy for U.S. Blacks Shorter Than That of Whites 2Health News:City Birds Sing Differently Than Their Country Cousins 2
... LCD color monitor ... of the icons for ... your desired choices for ... measure much smaller pupils ...
Portable, easy to align, automatic measurement, automatic fogging. Accurate and dependable readings. Infrared printer communication. Rechargeable battery. Integrates with the TRS-2100 and EPIC-2100 r...
... frequency doubled Nd:YAG laser is mounted on ... be selected between 0.2 and 2.0 mJ. ... 400 and 700 microns. Knobs for laser ... located on the laser head. The laser ...
... II Glaucoma Laser System features a patented ... open-angle glaucoma. It selectively targets pigmented cells ... The Selecta II is equipped with a ... of light, which induces the same cell ...
Medicine Products: